What is the current stock price of Finch Therapeutics Group, Inc. (FNCH)?

As of the latest market data, Finch Therapeutics Group, Inc. (FNCH) is trading at $8.35. The stock has seen a loss of -4.02% today.

Does Finch Therapeutics Group, Inc. (FNCH) pay a dividend?

Based on current data, Finch Therapeutics Group, Inc. does not have a confirmed active dividend policy.

What is the market cap of Finch Therapeutics Group, Inc.?

The current market capitalization of Finch Therapeutics Group, Inc. (FNCH) is approximately unavailable.

FNCH

Finch Therapeutics Group, Inc.·Healthcare

8.35

4.023%(−0.35)

Market Closed

9.20

10.180%(+0.85)

After Hours

Last Updated: — ET

52W L: $2.0052W H: $16.10

FNCH NEWS

defenseworld.net

Mar 19

Finch Therapeutics Group (NASDAQ:FNCH) Stock Price Down 2.7% – Here’s What Happened

Finch Therapeutics Group, Inc. (NASDAQ: FNCH - Get Free Report) dropped 2.7% during trading on Wednesday. The stock traded as low as $12.50 and last traded at $12.50. Approximately 283 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 1,590 shares. The stock had previously closed at $12.85.

defenseworld.net

Jan 22

Critical Contrast: Eloxx Pharmaceuticals (NASDAQ:ELOX) & Finch Therapeutics Group (NASDAQ:FNCH)

Risk and Volatility Eloxx Pharmaceuticals has a beta of -1720.35, suggesting that its share price is 172,135% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Profitability This table compares Eloxx Pharmaceuticals and Finch Therapeutics Group's

defenseworld.net

Jan 22

Contrasting Finch Therapeutics Group (NASDAQ:FNCH) and Eloxx Pharmaceuticals (NASDAQ:ELOX)

Profitability This table compares Finch Therapeutics Group and Eloxx Pharmaceuticals' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Finch Therapeutics Group N/A -69.14% -26.92% Eloxx Pharmaceuticals N/A N/A N/A Earnings and Valuation This table compares Finch Therapeutics Group and Eloxx Pharmaceuticals"s revenue, earnings per share and

Company Profile

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2021-03-19

Beta

1.17

Websitewww.finchtherapeutics.com↗